MARKET WIREReuters • 1h ago
COMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag - ReutersCOMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag Reuters
Why GRCE Stock dropped -3.48% Today — RQD Quant Desk Flash
$1.94 -3.48% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.92
Grace Therapeutics Inc. (GRCE) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $40.8M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on GRCE Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is GRCE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Grace Therapeutics Inc. (NASDAQ: GRCE) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.94 (-3.48% 1D, market cap $40.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, GRCE ranks #781 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does GRCE compare to ATHE and DWTX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GRCE carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -18.9%. By comparison, ATHE (Alterity Therapeutics Limited) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $40.7M) and DWTX (Dogwood Therapeutics Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -32.3%, cap $41.8M). Among the 5-stock peer group, GRCE leads on earnings multiple (N/A) while GRCE leads on capital efficiency (-18.9% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for GRCE?
▼
Per GRCE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001444192), Grace Therapeutics Inc. generated $0 in revenue, -$7.8M in net income, and -$8.9M in free cash flow against $68.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.92 (-0.82%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-11.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GRCE)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (32/100 Composite)
🔍 WHY GRCE SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (31% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (25% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$2.02-6.9% Next Q
40
Q2 (-2Q)Grade E$1.88-3.7% Next Q
37
Q3 (-1Q)Grade E$1.81+7.2% Next Q
35
CurrentGrade E$1.94-9.2% Hist 90D α
32
Trajectory: D (40) → E (32)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a GRCE Turnaround Squeeze
While GRCE currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.07) and Max Pain ($2.04) forces dealer call-delta covering toward $5.44.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $GRCE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “GRCE Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why GRCE Stock dropped -3.48% Today — RQD Quant Desk Flash
Grace Therapeutics Inc. (GRCE) dropped -3.48% to $1.94, trading at 8% of its 52-week range ($1.67 – $5.18). Stretched risk/reward at current multiples (-19% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 8% of its 52-week range ($1.67 – $5.18) with RSI-14 at 46.2 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.94 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live GRCE Headlines & Catalysts
MARKET WIREReuters • 2h ago
Saudi civil defence sounds all-clear after alerts in southern cities - ReutersSaudi civil defence sounds all-clear after alerts in southern cities Reuters
MARKET WIREReuters • 3h ago
World's energy supply buffers have been eroded, ADNOC CEO says - ReutersWorld's energy supply buffers have been eroded, ADNOC CEO says Reuters
MARKET WIREReuters • 4h ago
Gold rises on softer oil; markets parse Fed signals - ReutersGold rises on softer oil; markets parse Fed signals Reuters
MARKET WIREReuters • 5h ago
China's Xi says Middle East should not become battleground for great power rivalry - ReutersChina's Xi says Middle East should not become battleground for great power rivalry Reuters
CATALYSTReuters • 7h ago
Indian shares rise on Iran war talks, Reliance earnings beat - ReutersIndian shares rise on Iran war talks, Reliance earnings beat Reuters
CATALYSTReuters • 9h ago
Bank of England poised to raise rates but may push back on bets for more - ReutersBank of England poised to raise rates but may push back on bets for more Reuters
MARKET WIREReuters • 10h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GRCE)
- ✓Walkthrough of GRCE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
GRCE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -17.80%▼ DESCENDING CHANNEL
2026-11-02O $2.01H $2.01L $1.94C $1.94VOL 76.0K
RES: $2.33SUP: $1.63SMA50: $2.07SMA200: $2.81
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
GRCE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on GRCE today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for GRCE. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GRCE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GRCE)
Health Care Rank #781 of 1016
⚔️ ATHE vs GRCE Full Matrix →
1. Head-to-Head Health Care Peer Comparison (GRCE vs. ATHE, DWTX, ALDX, GRDX)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Grace Therapeutics Inc. (GRCE) ranks #781 by composite RQD confidence (32/100, grade E) and #772 by equity capitalization ($40.8M). Within this direct 5-issuer industry benchmark cohort, GRCE leads on earnings valuation at N/A trailing P/E, while GRCE leads on capital efficiency and profitability with -18.9% ROIC and — gross margin. ATHE currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with GRCE at 32/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| GRCE
ACTIVE
Grace Therapeutics Inc. | E | 32/100 | — | — | -18.9% | -3.48% | $40.8M | Benchmark Subject |
| ATHE Alterity Therapeutics Limited | D | 46/100 | — | — | — | +2.93% | $40.7M | /athe-vs-grce → |
| DWTX Dogwood Therapeutics Inc. | D- | 36/100 | — | — | -32.3% | -0.81% | $41.8M | /dwtx-vs-grce → |
| ALDX Aldeyra Therapeutics Inc. | D- | 40/100 | — | — | -35.0% | -3.58% | $39.8M | /aldx-vs-grce → |
| GRDX GridAI Technologies Corp. | D- | 41/100 | — | -30.0% | -20.0% | -5.38% | $38.9M | /grdx-vs-grce → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0001444192In its most recent audited fiscal period (FY2025, filed 2026-03-31), Grace Therapeutics Inc. (GRCE) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$7.8M, operating cash flow of -$8.9M, and free cash flow of -$8.9M (+40.5% YoY). On the balance sheet, GRCE closed FY2025 with $68.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2026-03-31 | $0 | -$7.8M | -$8.9M | -$8.9M | $68.5M | — |
| FY2024 (FY) | 2025-03-31 | $0 | -$9.6M | -$14.9M | -$14.9M | $61.2M | — |
| FY2023 (FY) | 2024-03-31 | $0 | -$12.9M | -$12.3M | -$12.3M | — | — |
3. GRCE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs GRCE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Grace Therapeutics Inc. (NASDAQ: GRCE) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.94 (-3.48% 1D, market cap $40.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, GRCE ranks #781 in composite RQD confidence.
How does GRCE compare to ATHE and DWTX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GRCE carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -18.9%. By comparison, ATHE (Alterity Therapeutics Limited) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $40.7M) and DWTX (Dogwood Therapeutics Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -32.3%, cap $41.8M). Among the 5-stock peer group, GRCE leads on earnings multiple (N/A) while GRCE leads on capital efficiency (-18.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for GRCE?
Per GRCE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001444192), Grace Therapeutics Inc. generated $0 in revenue, -$7.8M in net income, and -$8.9M in free cash flow against $68.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is GRCE trading relative to its 50-day, 200-day, and 52-week technical levels?
GRCE last traded at $1.94 (-3.48% on volume of 75,996 shares), positioning the stock -6.28% below its 50-day simple moving average ($2.07) and -30.96% below its 200-day simple moving average ($2.81). Across its 52-week range of $1.67 to $5.18, GRCE sits at the 7.7% percentile with a 14-day RSI of 46.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.70 to $2.18).
GRCE Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is GRCE stock moving today?
Why GRCE Stock dropped -3.48% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-19% return on capital) under elevated 10-year interest-rate pressure.